Adalimumab in psoriatic arthritis

Journal of Rheumatology

Volumn 39, Issue SUPPL. 89, 2012, Pages 77-81

  Salvarani, Carlo ^a   Pipitone, Nicolò ^a   Catanoso, Mariagrazia ^a   Chiarolanza, Ilaria ^a   Boiardi, Luigi ^a   Caruso, Andrea ^a   Pazzola, Giulia ^a   Macchioni, Pierluigi ^a   Di Lernia, Vito ^b   Albertini, Giuseppe ^b  

^a Hospital of Reggio Emilia   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

Adalimumab; Psoriasis; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

BONE EROSION; BONE MARROW EDEMA; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYARTHRITIS; PRIORITY JOURNAL; PSORIASIS SEVERITY INDEX; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; DRUG ANTAGONISM; EVIDENCE BASED MEDICINE; HOSPITALIZATION; IMMUNOLOGY; METABOLISM; REVIEW; TIME; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, PSORIATIC; EVIDENCE-BASED MEDICINE; HUMANS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864417044     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120251     Document Type: Conference Paper

References (34)

1. Gladman DD. Psoriatic arthritis. Baillieres Clin Rheumatol 1995;9:319-29.
2. Salvarani C, Olivieri I, Cantini F, Macchioni L, Boiardi L. Psoriatic arthritis. Curr Opin Rheumatol 1998;10:299-305. (Pubitemid 28421242)
3. Salvarani C, Lo Scocco G, Macchioni P, Cremonesi T, Rossi F, Mantovani W, et al. Prevalence of psoriatic arthritis in Italian psoriatic patients. J Rheumatol 1995;22:1499-503.
4. Olivieri I, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, et al. The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology 2008;47:1664-70.
5. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA) - an analysis of 220 patients. Q J Med 1987;62:127-41. (Pubitemid 17042878)
6. Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990;17:809-12. (Pubitemid 20213507)
7. Gladman DD. Psoriatic arthritis. Rheum Dis Clin North Am 1998;24:829-44. (Pubitemid 28524026)
8. Kavanaugh A, Ritchlin C, Boehncke WH. Quality indicators in psoriatic arthritis. Clin Exp Rheumatol 2007;6 Suppl 47:98-101.
9. Helliwell PS, Hickling P, Wright V. Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis? Ann Rheum Dis 1998;57:135-40.
10. Gladman DD. Mortality in psoriatic arthritis. Clin Exp Rheumatol 2008;5 Suppl 51:S62-5.
11. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939-50. (Pubitemid 38725106)
12. Black RL, O'Brien WM, Van Scott EJ, Auerbach R, Eisen AZ, Bunim JJ. Methotrexate therapy in psoriatic arthritis. Double-blind study on 21 patients. J Am Med Assoc 1964;189:743-7.
13. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013-20.
14. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999;42:2325-9. (Pubitemid 30333412)
15. Olivieri I, Salvarani C, Cantini F, Macchioni L, Padula A, Niccoli L, et al. Therapy with cyclosporine in psoriatic arthritis. Semin Arthritis Rheum 1997;27:36-43. (Pubitemid 27374247)
16. Salvarani C, Cantini F, Olivieri I. Disease-modifying antirheumatic drug therapy for psoriatic arthritis. Clin Exp Rheumatol 2002;6 Suppl 28:S71-5.
17. Salvarani C, Macchioni P, Olivieri I, Marchesoni A, Cutolo M, Ferraccioli G, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001;28:2274-82. (Pubitemid 32947875)
18. Pipitone N, Kingsley GH, Manzo A, Scott DL, Pitzalis C. Current concepts and new developments in the treatment of psoriatic arthritis. Rheumatology 2003;42:1138-48. (Pubitemid 37258474)
19. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994;96:146-51. (Pubitemid 24213812)
20. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998;25:1544-52. (Pubitemid 28364761)
21. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001;44:2112-7. (Pubitemid 33644055)
22. Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008;35:883-90. (Pubitemid 351747132)
23. Saad AA, Ashcroft DM, Watson KD, Symmons DP, Noyce PR, Hyrich KL. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology 2010;49:697-705.
24. Gladman DD, Sampalis JS, Illouz O, Guérette B. Response to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol 2010;37:1898-906.
25. Van den Bosch F, Manger B, Goupille P, McHugh N, Rødevand E, Holck P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010;69:394-9.
26. Anandarajah AP, Ory P, Salonen D, Feng C, Wong RL, Ritchlin CT. Effect of adalimumab on joint disease: features of patients with psoriatic arthritis detected by magnetic resonance imaging. Ann Rheum Dis 2010;69:206-9.
27. Karanikolas GN, Koukli E-M, Katsalira A, Arida A, Petrou D, Komninou E, et al. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheumatol 2011;38:2466-74.
28. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89. (Pubitemid 41447111)
29. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of psoriatic arthritis. Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007;56:476-88.
30. Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68:702-9.
31. Gladman DD, Mease PJ, Choy EH, Ritchlin CT, Perdok RJ, Sasso EH. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther 2010;12:R113.
32. Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007;34:1040-50. (Pubitemid 46774851)
33. Salvarani C, Pipitone N, Marchesoni A, Cantini F, Cauli A, Lubrano E, et al. Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin Exp Rheumatol 2011;3 Suppl 66:S28-41.
34. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889-94.